Regeneron (REGN) Tops Q3 EPS by 40c; EYLEA Sales Rose 16%

November 4, 2016 6:31 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Regeneron (NASDAQ: REGN) reported Q3 EPS of $3.13, $0.40 better than the analyst estimate of $2.73. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.29 billion.

EYLEA sales rose 16% to $854 million, from $734 million in Q315.

2016 Financial Guidance(3)

The Company's updated full year 2016 financial guidance consists of the following components:

EYLEA U.S. net product sales

23% - 25% growth over 2015

(previously 20% - 25% growth over 2015)

Sanofi reimbursement of Regeneron commercialization-related expenses

$310 million - $335 million

(previously $310 million - $340 million)

Non-GAAP unreimbursed R&D(2) (4)

$945 million - $975 million

(previously $970 million - $1.01 billion)

Non-GAAP SG&A(2) (4)

$965 million - $995 million

(previously $980 million - $1.02 billion)

Effective tax rate

29% - 33%

(previously 33% - 41%)

Capital expenditures

$480 million - $510 million

(previously $480 million - $530 million)

For earnings history and earnings-related data on Regeneron (REGN) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment